At 9 am this morning, Dendreon Corporation (Nasdaq: DNDN) announced the long awaited interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B). The clinical trial is designed to assess the safety and efficacy of the investigational active cellular immunotherapy Provenge® (sipuleucel-T) in men with metastatic [...]
GTx, Inc. (Nasdaq: GTXI) has conducted a number of clinical trials using toremifene citrate in both the treatment of breast and prostate cancer. Older women and men as well as women and men being treated for both breast and prostate cancers are subject to bone loss leading to an increased risk of falls and fractures. [...]
High Intensity Focused Ultrasound (HIFU) is a minimally invasive procedure that uses ultrasound energy to destroy cancerous tissue with focused sound waves. It has been used for a period of time in both Europe and Mexico as a primary prostate cancer treatment. Currently, in the United States there is a phase III trial being conducted [...]
Once we develop metastatic androgen-independent prostate cancer and experience disease progression after receiving docetaxel-based chemotherapy we have no approved treatment options. We have hit the proverbial wall! In the process of attempting to develop additional treatments, ImClone Systems Inc. (NASDAQ: IMCL), announced the beginning of a Phase II clinical trial for men with advanced prostate [...]
As my regular readers probably have noted from prior posts, I am a strong advocate for research and the development of a prostate cancer vaccine. A cancer vaccine is different from the more “common” types of vaccines that are familiar to us. The “common” vaccines (i.e. tetanus or polio) are administered prior to having an [...]